Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 3 Myelodysplastic Syndromes 2 Hematologic Neoplasms 2 Triple Negative Breast Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Myelodysplastic-Myeloproliferative Diseases 1 Mycoses 1 Mucormycosis 1 Genetic Predisposition to Disease 1 Candidiasis 1 Breast Neoplasms 1 Aspergillosis 1

Interventions

Fulvestrant 58 Trastuzumab 49 Capecitabine 48 Letrozole 45 pembrolizumab 41 Carboplatin 41 Paclitaxel 39 Cyclophosphamide 38 ribociclib 37 pertuzumab 36 abemaciclib 36 Blood Specimen Collection 31 Specimen Handling 28 trastuzumab deruxtecan 27 Docetaxel 27 Surveys and Questionnaires 26 Anastrozole 25 exemestane 24 Tamoxifen 24 palbociclib 21 130-nm albumin-bound paclitaxel 21 Magnetic Resonance Spectroscopy 20 Biopsy 19 sacituzumab govitecan 18 eribulin 18 Radiotherapy 18 Gemcitabine 18 olaparib 17 Injections 17 Epirubicin 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Breast Neoplasms × posaconazole × Clear all

NCT06802757 2026-02-25

PRISM-TNBC

Shandong Cancer Hospital and Institute

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡